Megan Collett, APRN
Nurse Practitioner · Lexington, KYNPI 1134580145
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,261 of the $13,402 with a category attached, or 76.6%. 57 manufacturers reported payments, led by EMD Serono, Inc. at 26.7% of the total. Reporting peaked in 2024 at $5,498 and has fallen 53.8% since, to $2,542 in 2025. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 640 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$4K
- AbbVie$3K
- AstraZeneca$694
- Biogen$519
- Pfizer$480
- Novartis$449
- plus $5K from 51 others
What the payments were for
- Consulting fees$2,58519%
- Food & beverage$10,26177%
- Education$5564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,402 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 150 | $171,627 |
| NuplazidPimavanserin Tartrate | 21 | $106,363 |
| IngrezzaValbenazine Tosylate | 12 | $101,158 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $94,850 |
| BafiertamMonomethyl Fumarate | 11 | $74,051 |
| Topiramate ErTopiramate | 65 | $62,713 |
| QuliptaAtogepant | 48 | $61,985 |
| Emgality PenGalcanezumab-Gnlm | 73 | $59,647 |
| Aimovig AutoinjectorErenumab-Aooe | 69 | $57,807 |
| Nurtec OdtRimegepant Sulfate | 51 | $50,508 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 45 | $42,162 |
| Dalfampridine ErDalfampridine | 50 | $30,866 |
| RexultiBrexpiprazole | 11 | $26,858 |
| Ajovy SyringeFremanezumab-Vfrm | 22 | $23,863 |
| Teriflunomide | 28 | $16,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Linzess | $2,581 | $244,770209 claims |
| Acadia Pharmaceuticals IncNuplazid | $132 | $106,36321 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $70 | $101,15812 claims |
| PfizerNurtec Odt | $480 | $50,50851 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $109 | $26,85811 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $60 | $13,76811 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $16 | $12,13113 claims |
| UCB, Inc.Neupro | $225 | $11,32312 claims |
| Lilly USA, LLCReyvow | $401 | $8,83112 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $104 | $2,48819 claims |
| Upsher-smith Laboratories LLCTopiramate | $33 | $1,569167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Lexington
- Rachael BradfordLexington$447K
- Juawanna SchullerLexington$26K
- Jessica SchorckLexington$26K
- Amelia HendricksonLexington$22K
- Amy NydamLexington$11K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.